Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?
about
Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's DiseaseNeuroanatomical changes in Parkinson's disease in relation to cognition: An updateNeuroimaging of Parkinson's disease: Expanding views.Fronto-striatal gray matter contributions to discrimination learning in Parkinson's disease.Advanced magnetic resonance imaging of neurodegenerative diseases.The neurobiological basis of cognitive impairment in Parkinson's disease.Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Initial cognitive decline is associated with cortical thinning in early Parkinson disease.Tracking Parkinson's Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate DiseaseCigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's DiseaseNeurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.Central Pain Processing in Early-Stage Parkinson's Disease: A Laser Pain fMRI Study.Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.Classification of brain disease in magnetic resonance images using two-stage local feature fusionMild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson's disease.Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson's disease.Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.Computer-based magnetic resonance imaging as a tool in clinical diagnosis in neurodegenerative diseases.Progression of subcortical atrophy in mild Parkinson's disease and its impact on cognition.Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.Lewy Body Disorders.On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivity-based single-subject classification.Quantitative Evaluation of Intensity Inhomogeneity Correction Methods for Structural MR Brain Images.Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.The evolution of diffusion tensor imaging in Parkinson's disease research.Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.Microstructural changes in white matter associated with freezing of gait in Parkinson's disease.Alterations of functional and structural connectivity of freezing of gait in Parkinson's disease.Cerebellar atrophy in Parkinson's disease and its implication for network connectivity.
P2860
Q26802087-288B5512-A18A-471B-8A1B-9C8C7D14DBB1Q28067803-B0A87EAD-9DA3-44DB-9474-DF811D50D1F2Q28387732-6658001D-7B4E-48FF-B294-8D3F5A2DCFCCQ30559309-E6A6219C-2177-4814-96F8-40435414D949Q31142517-D6E2E36D-9D21-42BA-9B0D-E53B757BA5B0Q33724698-5546CFF9-BE68-47D1-B1C4-FD7DBB805920Q33917300-BFB43D6F-B800-409A-9B1F-F00A18608EF9Q33927210-E560B1DA-67D2-44BF-B9E5-9CB0D920A7D2Q35880760-6B8F278C-8EC7-46D9-BCC9-D61A6E08D8EDQ35912013-02EEF936-7FF4-4E1F-A8E6-D72E301F123CQ35978159-72492D16-A3F2-46BB-B4AC-15292BCFE2D1Q36173022-5AF2C50E-195D-4874-B3AD-081B42E6E672Q36175217-B094D6B7-E2AE-4714-8BBB-83C3E32283C2Q36282942-04358DE0-6BBF-473A-B363-239F7479F6CCQ37141684-3C156B23-A97C-4512-A5B2-0DC4282FBE87Q37267022-6E0EF163-176F-48B3-8608-9C8897F9A11BQ37470123-28C8DDED-8DA9-4400-B9B8-F8768853198EQ37697485-7C4BDE16-1A96-41C3-AB64-77F5197FFFD4Q38710593-00C3F4A9-22E7-4C0B-85CB-1EABBD4EE30EQ38784016-36A3BD41-4936-4704-81A4-2AA8030D3DE0Q39042377-1EC00907-19CF-43FD-B86C-7F42693F3506Q39243369-AAC3B665-9B31-47FC-806E-F97214E2BEF9Q40055947-0F7FE735-B282-4BB7-A66D-2D9A6059C0DBQ40607807-71E4699A-4854-4D33-80C9-13C710A91C3DQ41566472-39C7A824-0B9F-4834-8D5F-4F1593893F11Q45000656-37AF5894-CCF3-4CDA-9836-04AC187405E8Q46843908-8B51D084-9FBC-4B5C-8091-F380AC18EEE1Q48349758-45DA3EE4-D5E6-4432-B942-D635330BE3BBQ48711531-3A6AFC49-10C8-43FA-8384-F52755213B1AQ48958384-874BB1EC-073A-466B-B89B-6D15B8E404A7
P2860
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?
@en
type
label
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?
@en
prefLabel
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?
@en
P2860
P50
P356
P1433
P1476
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?
@en
P2093
Gordon W Duncan
P2860
P304
P356
10.1002/MDS.25352
P407
P577
2013-02-28T00:00:00Z